Cargando…

The prediction of early progressive disease in patients with hepatocellular carcinoma receiving atezolizumab plus bevacizumab

BACKGROUND AND AIMS: The IMbrave 150 trial revealed the usefulness of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma (HCC), making it now considered the first‐line systemic chemotherapy agent for HCC. The present study investigated factors associated wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Takeuchi, Yasuto, Nouso, Kazuhiro, Fujioka, Shin‐ichi, Kariyama, Kazuya, Kobashi, Haruhiko, Uematsu, Shuji, Moriya, Akio, Hagihara, Hiroaki, Takabatake, Hiroyuki, Nakamura, Shinichiro, Yabushita, Kazuhisa, Kikuchi, Tatsuya, Oyama, Atsushi, Adachi, Takuya, Wada, Nozomu, Onishi, Hideki, Shiraha, Hidenori, Takaki, Akinobu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	RESEARCH ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10523973/ https://www.ncbi.nlm.nih.gov/pubmed/37537956 http://dx.doi.org/10.1002/cam4.6369

Ejemplares similares

Management of Cirrhotic Ascites under the Add-on Administration of Tolvaptan
por: Adachi, Takuya, et al.
Publicado: (2021)

Study Protocol for a Trial: A Single-Arm, Open-Labeled Study Evaluating Transcatheter Arterial Embolization Plus Everolimus Combination Therapy for Patients With Liver Metastasis of Gastroenteropancreatic Neuroendocrine Tumors
por: Takeuchi, Yasuto, et al.
Publicado: (2022)

Oxidative stress-related markers as prognostic factors for patients with primary sclerosing cholangitis in Japan
por: Oyama, Atsushi, et al.
Publicado: (2023)

Hepatitis B virus core promoter mutations G1613A and C1653T are significantly associated with hepatocellular carcinoma in genotype C HBV-infected patients
por: Tatsukawa, Masashi, et al.
Publicado: (2011)

Hepatic stellate cells promote upregulation of epithelial cell adhesion molecule and epithelial-mesenchymal transition in hepatic cancer cells
por: NAGAHARA, TERUYA, et al.
Publicado: (2015)

Effect of butyrate‐producing enterobacteria on advanced hepatocellular carcinoma treatment with atezolizumab and bevacizumab
por: Nouso, Kazuhiro, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience
por: Hiraoka, Atsushi, et al.
Publicado: (2021)

Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma
por: KATAOKA, JUNRO, et al.
Publicado: (2016)

Loss of Runt-related transcription factor 3 induces resistance to 5-fluorouracil and cisplatin in hepatocellular carcinoma
por: Kataoka, Junro, et al.
Publicado: (2017)

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis
por: Tada, Toshifumi, et al.
Publicado: (2022)

Relationship of Atezolizumab plus Bevacizumab Treatment with Muscle Volume Loss in Unresectable Hepatocellular Carcinoma Patients: Multicenter Analysis
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Pro-angiogenic cytokines for prediction of outcomes in patients with advanced hepatocellular carcinoma
por: Miyahara, K, et al.
Publicado: (2013)

Adverse events as potential predictive factors of therapeutic activity in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Tada, Toshifumi, et al.
Publicado: (2022)

Does first‐line treatment have prognostic impact for unresectable HCC?—Atezolizumab plus bevacizumab versus lenvatinib
por: Hiraoka, Atsushi, et al.
Publicado: (2022)

Oxidative Stress Management in Chronic Liver Diseases and Hepatocellular Carcinoma
por: Uchida, Daisuke, et al.
Publicado: (2020)

A subclinical high tricuspid regurgitation pressure gradient independent of the mean pulmonary artery pressure is a risk factor for the survival after living donor liver transplantation
por: Saragai, Yosuke, et al.
Publicado: (2018)

Comparative efficacy and safety of atezolizumab and bevacizumab between hepatocellular carcinoma patients with viral and non‐viral infection: A Japanese multicenter observational study
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Usefulness of Tumor Marker Score for Predicting the Prognosis of Hepatocellular Carcinoma Patients Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Tanaka, Kazunari, et al.
Publicado: (2023)

New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation study
por: Tada, Toshifumi, et al.
Publicado: (2022)

Twist expression promotes migration and invasion in hepatocellular carcinoma
por: Matsuo, Noriyuki, et al.
Publicado: (2009)

Loss of runt-related transcription factor 3 expression leads hepatocellular carcinoma cells to escape apoptosis
por: Nakanishi, Yutaka, et al.
Publicado: (2011)

The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC‐GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysis
por: Hatanaka, Takeshi, et al.
Publicado: (2022)

Factors associated with the response to atezolizumab/bevacizumab combination therapy for hepatocellular carcinoma
por: Yano, Yoshihiko, et al.
Publicado: (2023)

Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab
por: Suga, Takayoshi, et al.
Publicado: (2023)

Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review
por: Ahmed, Faiza, et al.
Publicado: (2021)

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma
por: Eso, Yuji, et al.
Publicado: (2021)

L-Carnitine Prevents Progression of Non-Alcoholic Steatohepatitis in a Mouse Model with Upregulation of Mitochondrial Pathway
por: Ishikawa, Hisashi, et al.
Publicado: (2014)

Unraveling the Synergy between Atezolizumab and Bevacizumab for the Treatment of Hepatocellular Carcinoma
por: Brackenier, Cedric, et al.
Publicado: (2023)

Adjuvant atezolizumab-bevacizumab after curative therapy for hepatocellular carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Case Report: Atezolizumab plus bevacizumab for combined hepatocellular-cholangiocarcinoma
por: Satake, Tomoyuki, et al.
Publicado: (2023)

Adjuvant Atezolizumab-Bevacizumab after Resection or Ablation for Hepatocellular Carcinoma
por: Kudo, Masatoshi
Publicado: (2023)

Predicting Outcomes of Atezolizumab and Bevacizumab Treatment in Patients with Hepatocellular Carcinoma
por: Han, Ji Won, et al.
Publicado: (2023)

Therapeutic Efficacy and Safety of Lenvatinib after Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma
por: Yano, Shigeki, et al.
Publicado: (2023)

Early Prediction of Response Focused on Tumor Markers in Atezolizumab plus Bevacizumab Therapy for Hepatocellular Carcinoma
por: Tanabe, Norikazu, et al.
Publicado: (2023)

Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis
por: Yasunaka, Tetsuya, et al.
Publicado: (2011)

A preliminary study for constructing a bioartificial liver device with induced pluripotent stem cell-derived hepatocytes
por: Iwamuro, Masaya, et al.
Publicado: (2012)

Fibrolamellar hepatocellular carcinoma treated with atezolizumab and bevacizumab: two case reports
por: AL Zahrani, Ali, et al.
Publicado: (2021)

Atezolizumab/bevacizumab: Severe encephalitis and immune-mediated polyradiculoneuropathy: case report
Publicado: (2021)

Advanced hepatocellular carcinoma with response to lenvatinib after atezolizumab plus bevacizumab
por: Yano, Shigeki, et al.
Publicado: (2021)

A Case of Pseudoprogression in Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab
por: Watanabe, Yukinobu, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hd8le19fc22q919d70ms2eb83g